‘Big pharma made billions out of COVID-19 VACCINES!’: Hawley drops bombshell at explosive hearing

Key Concepts

• Pharmacovigilance: The practice of monitoring the effects of medical drugs after they have been licensed for use, especially to identify and evaluate previously unreported adverse reactions.
• Genotoxicity: The property of chemical agents that damages the genetic information within a cell, causing mutations.
• Biodistribution: The process of tracking where a drug or vaccine travels within the body after administration.
• SV40 Sequences: Simian Virus 40 sequences; specific DNA segments identified in the manufacturing plasmid of the Pfizer vaccine that were allegedly not disclosed to the public.
• Bayesian Methods: Statistical methods used in data mining to identify safety signals in adverse event reporting.
• PRR (Proportional Reporting Ratio): A statistical technique used in pharmacovigilance to detect signals of disproportionate reporting of adverse events.
• VSD (Vaccine Safety Datalink): A collaborative project between the CDC and several healthcare organizations to monitor vaccine safety.

---

1. Main Topics and Key Points

The transcript details a congressional hearing focused on the alleged failure of pharmaceutical companies and government agencies (FDA/CDC) to prioritize public safety over corporate profit during the COVID-19 pandemic. The primary argument is that the vaccine rollout functioned as a "profit machine" rather than a standard public health campaign.

• Inadequate Testing and Disclosure: Witnesses argued that pharmaceutical companies (specifically Pfizer and Moderna) were permitted by the FDA to bypass or "overly generously interpret" standard safety protocols, including genotoxicity, lipid nanoparticle, and biodistribution studies.
• Non-Disclosure of SV40 Sequences: A significant point of contention was the alleged non-disclosure by Pfizer regarding the presence of SV40 virus sequences in the plasmids used to manufacture the vaccine.
• Systemic Concealment: The testimony suggests that adverse event data was systematically downplayed or hidden. A specific example provided was the VSD program identifying signals for myocardial infarction and venous thromboembolism in May 2022, which were not disclosed to the public until a year later.

2. Real-World Applications and Case Studies

• The "Sweetheart Deal": The witness characterized the relationship between the government and pharma companies as a "sweetheart deal," where the government handled marketing and liability, allowing companies to generate billions in profit while offloading public health costs onto the American public.
• Marginalization of Experts: The witness noted that experts like Dr. Anna Shman and Dr. Buchelle (the "father and mother" of PRR methods) were ignored or told to "cease and desist" when they attempted to present data analysis that contradicted the official narrative.

3. Methodologies and Reform Recommendations

The witness proposed several structural changes to ensure future accountability:

• Separation of Powers: A greater degree of separation must be established between government regulatory bodies and pharmaceutical companies to prevent conflicts of interest.
• Standardized Data Collection: Companies should be mandated to use modified Bayesian methods and PRR methods for signal detection.
• Usage-Based Analysis: Adverse event rates should be calculated based on actual usage data rather than generalized reporting, a method the witness claims was successfully demonstrated but ignored by authorities.
• Moral Responsibility: The witness argued that companies must be held to a standard that exceeds the "letter of the law," requiring them to disclose risks even if regulators allow them to remain silent.

4. Notable Quotes

• "What we saw during COVID wasn't so much a public health campaign as it was a profit machine."
• "Systematically concealing from the public the true risks involved with this vaccine in a way that not only misled patients... but had the net effect of lining the pockets of the biggest pharma companies in the world—that is a disgrace."
• "Even if the government says we can get away with it, we're not going to." (Regarding the moral responsibility of manufacturers).

5. Synthesis and Conclusion

The testimony concludes that the COVID-19 vaccine rollout was characterized by a lack of transparency and a prioritization of corporate financial gain over patient safety. The witness emphasizes that the current regulatory framework is insufficient to protect the public, as it allows for the concealment of adverse event data and the marginalization of dissenting scientific experts. The core takeaway is the urgent need for legislative reform that mandates rigorous, transparent data analysis and enforces strict accountability for pharmaceutical manufacturers, regardless of their collaboration with government agencies.